Ad fontes!

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 3, 2010, Pages 260-

  Hoffner, Sven E ^a   Salfinger, Max ^b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b FLORIDA DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; EDITORIAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 77949533549     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (5)

1. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement, June 27, 2008. Geneva, Switzerland: WHO, 2008. http://www.who.int/tb/features-archive/policy-statement.pdf Accessed January 2010.
2. Kam K M, Sloutsky A, Yip C W, et al. Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis 2010; 14: 282-288.
3. Parsons L M, Somoskovi A, Urbanczik R, Salfinger M. Laboratory diagnostic aspects of drug-resistant tuberculosis. Front Biosci 2004; 9: 2086-2105.
4. Dong Y, Zhao X, Kreiswirth B N, Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: 2581-2584.
5. Schön T, Juréen P, Giske C G, et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 786-793.